Research Article
Effectiveness and Cost-Effectiveness of Sequential Treatment of Patients with Chronic Myeloid Leukemia in the United States: A Decision Analysis
Table 1
Sequential treatment strategies.
| | First-line TKI | Second-line TKI | Chemotherapy/stem-cell transplantation |
| | Chemotherapy | — | — | | Imatinib | — | Chemotherapy/stem-cell transplantation | | Bosutinib | — | Chemotherapy/stem-cell transplantation | | Dasatinib | — | Chemotherapy/stem-cell transplantation | | Nilotinib | — | Chemotherapy/stem-cell transplantation | | Imatinib | Bosutinib | Chemotherapy/stem-cell transplantation | | Imatinib | Dasatinib | Chemotherapy/stem-cell transplantation | | Imatinib | Nilotinib | Chemotherapy/stem-cell transplantation | | Imatinib | Ponatinib | Chemotherapy/stem-cell transplantation | | Bosutinib | Dasatinib | Chemotherapy/stem-cell transplantation | | Bosutinib | Nilotinib | Chemotherapy/stem-cell transplantation | | Bosutinib | Ponatinib | Chemotherapy/stem-cell transplantation | | Dasatinib | Bosutinib | Chemotherapy/stem-cell transplantation | | Dasatinib | Nilotinib | Chemotherapy/stem-cell transplantation | | Dasatinib | Ponatinib | Chemotherapy/stem-cell transplantation | | Nilotinib | Bosutinib | Chemotherapy/stem-cell transplantation | | Nilotinib | Dasatinib | Chemotherapy/stem-cell transplantation | | Nilotinib | Ponatinib | Chemotherapy/stem-cell transplantation |
|
|
TKI: tyrosine kinase inhibitor.
Hydroxyurea.
|
